Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We read with great interest the article by Treumer et al in the January 2010 issue of the journal, regarding the dual action of subretinal injection of recombinant tissue plasminogen activator (rtPA) and bevacizumab associated with pneumatic displacement in treating submacular haemorrhage secondary to age-related macular degeneration.1 Injecting both bevacizumab and rtPA in subretinal,2 or in intravitreal use,3–5 serves the purpose of treating both the subretinal haemorrhage and neovascularisation.
However, rtPA is a serine protease with its catalytic …
Competing interests None.
Provenance and peer review Not commissioned; not externally peer reviewed.